CorMedix Company Insiders
| CRMD Stock | USD 9.98 0.20 2.04% |
CorMedix employs about 82 people. The company is managed by 8 executives with a total tenure of roughly 192 years, averaging almost 24.0 years of service per executive, having 10.25 employees per reported executive. Evaluation of CorMedix's management performance can provide insight into the firm performance.
CorMedix |
CorMedix Management Team Effectiveness
The company has return on total asset (ROA) of (0.3769) % which means that it has lost $0.3769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. CorMedix's management efficiency ratios could be used to measure how well CorMedix manages its routine affairs as well as how well it operates its assets and liabilities.CorMedix Workforce Comparison
CorMedix is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,873. CorMedix holds roughly 82.0 in number of employees claiming about 2.85% of equities under Health Care industry.
CorMedix Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CorMedix insiders, such as employees or executives, is commonly permitted as long as it does not rely on CorMedix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CorMedix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zelnick Kaufman Beth over a month ago Acquisition by Zelnick Kaufman Beth of 200000 shares of CorMedix at 3.3 subject to Rule 16b-3 | ||
Erin Mistry over three months ago Acquisition by Erin Mistry of 1000 shares of CorMedix at 4.0 subject to Rule 16b-3 | ||
Erin Mistry over six months ago Acquisition by Erin Mistry of 50000 shares of CorMedix subject to Rule 16b-3 | ||
Dunton Alan W over six months ago Acquisition by Dunton Alan W of 30000 shares of CorMedix at 3.55 subject to Rule 16b-3 | ||
Todisco Joseph over six months ago Insider Trading | ||
Janet Dillione over six months ago Acquisition by Janet Dillione of 3583 shares of CorMedix subject to Rule 16b-3 | ||
Duncan Gregory Scott over six months ago Acquisition by Duncan Gregory Scott of 30000 shares of CorMedix at 3.55 subject to Rule 16b-3 | ||
Todisco Joseph over six months ago Acquisition by Todisco Joseph of 133333 shares of CorMedix subject to Rule 16b-3 |
CorMedix Notable Stakeholders
A CorMedix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CorMedix often face trade-offs trying to please all of them. CorMedix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CorMedix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Matthew MD | Executive CFO | Profile | |
| Kaufman Esq | Chief VP | Profile | |
| Joseph MBA | CEO Director | Profile | |
| Donna Ucci | Senior Quality | Profile | |
| Tushar Mukherjee | Senior Operations | Profile | |
| Phoebe Esq | Gen EVP | Profile | |
| Elizabeth BA | Executive Affairs | Profile | |
| Erin Mistry | Executive Officer | Profile |
About CorMedix Management Performance
The success or failure of an entity such as CorMedix often depends on how effective the management is. CorMedix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CorMedix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CorMedix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey. Cormedix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Please note, the presentation of CorMedix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CorMedix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CorMedix's management manipulating its earnings.
CorMedix Workforce Analysis
Traditionally, organizations such as CorMedix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CorMedix within its industry.CorMedix Manpower Efficiency
Return on CorMedix Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 565.1K | |
| Net Loss Per Executive | 5.8M | |
| Working Capital Per Employee | 829.9K | |
| Working Capital Per Executive | 8.5M |
Complementary Tools for CorMedix Stock analysis
When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |